Global Market Direct’s pharmaceuticals report, “Endotis Pharma - Product Pipeline Review - 2013” provides data on the Endotis Pharma’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Endotis Pharma’s corporate website, SEC filings, investor presentations and featured press releases, both from Endotis Pharma and industry-specific third party sources, put together by Global Markets Direct’s team.
- Endotis Pharma - Brief Endotis Pharma overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Endotis Pharma human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Endotis Pharma with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Endotis Pharma’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Endotis Pharma’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Endotis Pharma in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Endotis Pharma’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Endotis Pharma. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Endotis Pharma and identify potential opportunities in those areas.
Table Of Contents
Endotis Pharma - Product Pipeline Review - 2013 Table of Contents 2 List of Tables 3 List of Figures 3 Endotis Pharma Snapshot 4 Endotis Pharma Overview 4 Key Information 4 Key Facts 4 Endotis Pharma - Research and Development Overview 5 Key Therapeutic Areas 5 Endotis Pharma - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Endotis Pharma - Pipeline Products Glance 9 Endotis Pharma Clinical Stage Pipeline Products 9 Phase II Products/Combination Treatment Modalities 9 Phase I Products/Combination Treatment Modalities 10 Endotis Pharma - Early Stage Pipeline Products 11 Pre-Clinical Products/Combination Treatment Modalities 11 Endotis Pharma - Drug Profiles 12 EP-217609 12 Product Description 12 Mechanism of Action 12 RandD Progress 12 EP-37 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 EP-5001 15 Product Description 15 Mechanism of Action 15 RandD Progress 15 EP-80061 16 Product Description 16 Mechanism of Action 16 RandD Progress 16 fondaparinux sodium 17 Product Description 17 Mechanism of Action 17 RandD Progress 17 Endotis Pharma - Pipeline Analysis 18 Endotis Pharma - Pipeline Products by Therapeutic Class 18 Endotis Pharma - Pipeline Products by Route of Administration 19 Endotis Pharma - Pipeline Products By Mechanism of Action 20 Endotis Pharma - Recent Pipeline Updates 21 Endotis Pharma - Dormant Projects 22 Endotis Pharma - Locations And Subsidiaries 23 Head Office 23 Other Locations and Subsidiaries 23 Appendix 24 Methodology 24 Coverage 24 Secondary Research 24 Primary Research 24 Expert Panel Validation 24 Contact Us 25 Disclaimer 25
List of Tables
Endotis Pharma, Key Information 4 Endotis Pharma, Key Facts 4 Endotis Pharma - Pipeline by Indication, 2013 6 Endotis Pharma - Pipeline by Stage of Development, 2013 7 Endotis Pharma - Monotherapy Products in Pipeline, 2013 8 Endotis Pharma - Phase II, 2013 9 Endotis Pharma - Phase I, 2013 10 Endotis Pharma - Pre-Clinical, 2013 11 Endotis Pharma - Pipeline By Therapeutic Class, 2013 18 Endotis Pharma - Pipeline By Route of Administration, 2013 19 Endotis Pharma - Pipeline Products By Mechanism of Action, 2013 20 Endotis Pharma - Recent Pipeline Updates, 2013 21 Endotis Pharma - Dormant Developmental Projects,2013 22 Endotis Pharma, Other Locations 23
List of Figures
Endotis Pharma - Pipeline by Indication, 2013 6 Endotis Pharma - Pipeline by Stage of Development, 2013 7 Endotis Pharma - Monotherapy Products in Pipeline, 2013 8 Endotis Pharma - Pipeline By Therapeutic Class, 2013 18 Endotis Pharma - Pipeline By Route of Administration, 2013 19 Endotis Pharma - Pipeline Products By Mechanism of Action, 2013 20